1-(2-bromoethyl)-2,3-dihydro-6-methoxy-1H-indene | 178676-91-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-(2-bromoethyl)-2,3-dihydro-6-methoxy-1H-indene
• 英文别名: 1-(2-bromoethyl)-6-methoxyindan；1-(2-bromoethyl)-6-methoxy-2,3-dihydro-1H-indene
• CAS: 178676-91-0
• 化学式: C₁₂H₁₅BrO
• 分子量: 255.155
• InChiKey: MLCVRPVHVKILSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-bromoethyl)-2,3-dihydro-6-methoxy-1H-indene 在 Raney-Nickel W₂ 氨 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二甲基亚砜 为溶剂， 60.0 ℃ 、400.0 kPa 条件下， 反应 0.67h， 生成 6-Methoxy-1-[3-(trifluoroacetylamino)propyl]indan
  参考文献：
  名称：

  Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists

  摘要：

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.

  DOI：

  10.1021/jm020114g
• 作为产物：
  描述：

  ethyl 2-(6-methoxy-2,3-dihydro-1H-inden-1-ylidene)acetate 在 5% Pd on active carbon lithium aluminium tetrahydride 、 氢气 、 三溴化磷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.25h， 生成 1-(2-bromoethyl)-2,3-dihydro-6-methoxy-1H-indene
  参考文献：
  名称：

  Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists

  摘要：

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.

  DOI：

  10.1021/jm020114g

文献信息

• Benzocycloalkene compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06235789B1

  公开（公告）日：2001-05-22

  A compound of the formula wherein R1 and R2 are H, a hydrocarbon group or a heterocyclic group, or R1 and R2 are combinedly a spiro ring; R3 is a hydrocarbon group, a substituted amino group, a substituted hydroxyl group or a heterocyclic group; R4 is H or alkyl; ring A is a substituted benzene ring; m and n denote 1 to 4; overscore (.........)} means a single or double bond or a salt, a process of producing thereof and a composition having a binding affinity for melatonin receptor.

  式中R1和R2为H、一个碳氢基团或一个杂环基团，或者R1和R2合并为一个螺环；R3为一个碳氢基团、一个取代氨基团、一个取代羟基团或一个杂环基团；R4为H或烷基；环A为一个取代苯环；m和n表示1到4；overscore (.........)}表示一个单键或双键或盐，一种生产方法及具有对褪黑激素受体具有结合亲和力的组合物。
• BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0781271A1

  公开（公告）日：1997-07-02
• US6235789B1
  申请人：——

  公开号：US6235789B1

  公开（公告）日：2001-05-22
• [EN] BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE<br/>[FR] COMPOSES BENZOCYCLOALCENES, LEUR PRODUCTION ET LEUR UTILISATION
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：WO1996008466A1

  公开（公告）日：1996-03-21

  (EN) A compound of formula (I) wherein R1 and R2 are H, a hydrocarbon group or a heterocyclic group, or R1 and R2 are combinedly a spiro ring; R3 is a hydrocarbon group, a substituted amino group, a substituted hydroxyl group or a heterocyclic group; R4 is H or alkyl; ring A is a substituted benzene ring; m and n denote 1 to 4; ......... means a single or double bond or a salt, a process of producing thereof and a composition having a binding affinity for melatonin receptor.(FR) Composés de la formule (I) dans laquelle R1 et R2 sont H, un groupe hydrocarbure ou un groupe hétérocyclique, ou bien sont combinés en une liaison spiro; R3 est un groupe hydrocarbure, un groupe amino substitué, un groupe hydroxyle ou un groupe hétérocyclique substitué; R4 est H ou un alkyle; la liaison A est une liaison benzène substituée; m et n sont des nombres allant de 1 à 4; ......... exprime une liaison simple ou double ou un sel. L'invention porte également sur le procédé d'obtention d'un tel composé et sur une composition présentant une affinité de liaison pour le récepteur de mélatonine.
• Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists
  作者：Kohji Fukatsu、Osamu Uchikawa、Mitsuru Kawada、Toru Yamano、Masayuki Yamashita、Koki Kato、Keisuke Hirai、Shuji Hinuma、Masaomi Miyamoto、Shigenori Ohkawa

  DOI：10.1021/jm020114g

  日期：2002.9.1

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.